Zacks: Brokerages Expect Aptose Biosciences Inc. (NASDAQ:APTO) to Post -$0.13 Earnings Per Share

Wall Street brokerages expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to announce earnings of ($0.13) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.14). Aptose Biosciences reported earnings of ($0.16) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.8%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.68) to ($0.55). For the next financial year, analysts forecast that the company will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.69) to ($0.68). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01.



Several research analysts recently commented on APTO shares. HC Wainwright lowered their target price on Aptose Biosciences from $8.50 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, May 23rd. Finally, Zacks Investment Research cut Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $5.25.

APTO opened at $2.38 on Tuesday. Aptose Biosciences has a 12 month low of $1.57 and a 12 month high of $3.20. The stock has a market capitalization of $148.04 million, a price-to-earnings ratio of -2.77 and a beta of 1.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.27 and a quick ratio of 11.27. The business has a fifty day moving average price of $2.65 and a 200 day moving average price of $2.16.

A number of hedge funds and other institutional investors have recently made changes to their positions in APTO. Point72 Asset Management L.P. purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $5,742,000. Man Group plc purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $3,867,000. DRW Securities LLC lifted its holdings in Aptose Biosciences by 30.8% during the 2nd quarter. DRW Securities LLC now owns 3,347,018 shares of the biotechnology company’s stock worth $8,736,000 after buying an additional 788,560 shares during the last quarter. Sigma Planning Corp purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $572,000. Finally, Sanders Morris Harris LLC purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $572,000. 6.74% of the stock is owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.